News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
268,706 Results
Type
Article (14500)
Company Profile (256)
Press Release (253950)
Section
Business (81950)
Career Advice (154)
Deals (13764)
Drug Delivery (28)
Drug Development (53471)
Employer Resources (33)
FDA (6141)
Job Trends (5311)
News (150844)
Policy (10961)
Tag
Academia (918)
Africa (151)
Allergies (30)
Alliances (21943)
Alzheimer's disease (699)
Antibody-drug conjugate (ADC) (32)
Approvals (6115)
Arizona (39)
Artificial intelligence (35)
Asia (17442)
Australia (2871)
Bankruptcy (101)
Best Places to Work (4536)
Biotechnology (215)
C2C Services and Suppliers (10750)
California (1359)
Canada (535)
Cancer (368)
Career advice (134)
CAR-T (35)
Cell therapy (106)
China (100)
Clinical research (41981)
Collaboration (106)
Colorado (44)
Compensation (43)
Connecticut (48)
COVID-19 (994)
Cystic fibrosis (66)
Data (331)
Diabetes (46)
Diagnostics (1181)
Earnings (29777)
Employer resources (31)
Europe (38303)
Events (47902)
Executive appointments (109)
FDA (6305)
Florida (149)
Funding (113)
Gene therapy (90)
GLP-1 (273)
Government (1161)
Healthcare (6787)
Hotbed/Location (191275)
Illinois (86)
Indiana (50)
Infectious disease (1007)
Inflammatory bowel disease (80)
IPO (7481)
Job creations (910)
Job search strategy (130)
Kansas (54)
Layoffs (183)
Legal (1457)
Liver cancer (32)
Lung cancer (80)
Manufacturing (38)
Maryland (211)
Massachusetts (1125)
Medical device (2558)
Medtech (2559)
Mergers & acquisitions (6296)
Metabolic disorders (148)
Michigan (38)
Minnesota (67)
Neuroscience (837)
New Jersey (375)
New York (427)
NextGen Class of 2024 (2112)
Non-profit (884)
North Carolina (337)
Northern California (591)
Obesity (83)
Ohio (65)
Opinion (90)
Parkinson's disease (45)
Patents (37)
Pennsylvania (308)
People (25336)
Pharmaceutical (42)
Phase I (14492)
Phase II (19570)
Phase III (12633)
Pipeline (93)
Postmarket research (881)
Preclinical (5930)
Radiopharmaceuticals (199)
Rare diseases (124)
Real estate (1476)
Regulatory (8855)
Research institute (960)
South America (219)
Southern California (562)
Startups (1995)
Texas (131)
United States (5183)
Vaccines (143)
Washington State (160)
Weight loss (60)
Date
Today (100)
Last 7 days (373)
Last 30 days (1574)
Last 365 days (22041)
2024 (16097)
2023 (23223)
2022 (27886)
2021 (28887)
2020 (24509)
2019 (17051)
2018 (12430)
2017 (14722)
2016 (12645)
2015 (15324)
2014 (11032)
2013 (7936)
2012 (7892)
2011 (7947)
2010 (7714)
268,706 Results for "jupiter orphan therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Biotech Bay
ReCode Therapeutics Receives U.S. FDA Orphan Drug Designation for RCT1100 for the Treatment of Primary Ciliary Dyskinesia
ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for RCT1100 for the treatment of primary ciliary dyskinesia (PCD).
June 27, 2024
·
4 min read
Biotech Bay
Bluejay Therapeutics Receives Positive Opinion on Orphan Designation from the European Medicines Agency for BJT-778 for the Treatment of Chronic Hepatitis D
Bluejay Therapeutics announced that the European Medicines Agency has issued a positive opinion on the Company’s application for orphan designation for BJT-778 for the treatment of chronic hepatitis D.
May 29, 2024
·
2 min read
Lone Star Bio
Nanoscope Therapeutics to Present at the World Orphan Drug Congress 2024
Nanoscope Therapeutics Inc. today announced that Sulagna Bhattacharya , Chief Executive Officer and Samarendra Mohanty, PhD, President and Chief Scientific Officer will present and participate in a panel discussion at the World Orphan Drug Congress 2024, taking place from April 23-25, 2024 in Boston, Massachusetts.
April 17, 2024
·
2 min read
Press Releases
Astria Therapeutics Receives FDA Orphan Drug Designation for Navenibart (STAR-0215) for the Treatment of Hereditary Angioedema
September 30, 2024
·
7 min read
Press Releases
CAMP4 Therapeutics Secures Orphan Drug Designation for CMP-CPS-001 for the Treatment of Urea Cycle Disorders
September 18, 2024
·
2 min read
Press Releases
Lisata Therapeutics’ Certepetide Granted FDA Orphan Drug Designation for the Treatment of Cholangiocarcinoma
September 5, 2024
·
7 min read
FDA
Ingenium Therapeutics Novel NK Cell Therapy Receives Orphan Drug Designation From FDA
Ingenium Therapeutics, a leading innovator in next-generation NK cell therapies, announced today that its investigational therapy IGNK001 (Gengluecel) has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of acute myeloid leukemia (AML).
April 30, 2024
·
2 min read
Policy
Agomab Receives FDA Orphan Drug Designation for AGMB-447 in Idiopathic Pulmonary Fibrosis
Agomab Therapeutics NV announced that it has received Orphan Drug Designation from the U.S. Food and Drug Administration for AGMB-447, its inhaled, small molecule inhibitor of ALK5.
June 6, 2024
·
2 min read
FDA
Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma
Lisata Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (the “FDA”) has granted Orphan Drug Designation (“ODD”) to LSTA1.
April 9, 2024
·
6 min read
Biotech Bay
Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024
Alterity Therapeutics today announced that new data on ATH434 will be presented at the World Orphan Drug Congress USA 2024 taking place April 23-25, 2024 in Boston, MA.
April 10, 2024
·
8 min read
1 of 26,871
Next
